Ratings Alzinova AB

Equities

ALZ

SE0007413455

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.75 ^SEK	+8.02%		+28.68%	-42.34%

Jul. 09	Alzinova AB Announces All Patients in the High-Dose Cohort of the Phase 1B Study	CI
Jun. 18	Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALZINOVA AB	-42.34%	7.4M	-
MODERNA, INC.	+22.10%	46.55B	B-
LONZA GROUP AG	+46.45%	41.84B	A
IQVIA HOLDINGS INC.	-3.12%	40.84B	B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B	B
CELLTRION, INC.	-6.30%	28.27B	C
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B	B-
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B	B+
MEDPACE HOLDINGS, INC.	+44.52%	13.69B	C+
BIO-TECHNE CORPORATION	+0.19%	12.18B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes